By Melanie Senior
The European Union has always been vocal about its attempts to foster competitiveness and free trade. Under precisely this guise,...
Recent legal rulings in Europe may make it harder for innovators--particularly those companies deemed to be dominant in certain markets--to combat generics and parallel trade
By Melanie Senior
The European Union has always been vocal about its attempts to foster competitiveness and free trade. Under precisely this guise,...
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.